OPKO Health (NASDAQ:OPK) Director Buys $11,400.00 in Stock

Key Points

• Director John Paganelli bought 10,000 shares on March 20 at an average price of $1.14 (a $11,400 purchase), increasing his stake to 394,340 shares — a 2.6% ownership rise.
• OPK shares traded down to $1.12 on Friday with volume of 4.52M (well above the 2.34M average) and remain near their 52‑week low of $1.10 (52‑week high $1.83).
• OPKO beat quarterly EPS and revenue estimates (EPS: -$0.04 vs -$0.07; revenue: $148.5M vs $139.8M est) but revenue was down 19.1% YoY and margins are negative; analysts' consensus is a "Hold" with an average price target of $2.03.

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) Director John Paganelli acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, March 20th. The stock was purchased at an average cost of $1.14 per share, for a total transaction of $11,400.00. Following the purchase, the director owned 394,340 shares of the company's stock, valued at $449,547.60. This represents a 2.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

OPKO Health Stock Performance

Shares of OPK traded down $0.05 during midday trading on Friday, reaching $1.12. 4,521,528 shares of the stock were exchanged, compared to its average volume of 2,344,678. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.97 and a quick ratio of 3.52. OPKO Health, Inc. has a 52 week low of $1.10 and a 52 week high of $1.83. The company's 50 day moving average is $1.23 and its two-hundred day moving average is $1.34.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The business had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The business's revenue was down 19.1% compared to the same quarter last year. During the same period last year, the business posted $0.01 EPS. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in shares of OPKO Health by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company's stock valued at $13,940,000 after purchasing an additional 67,973 shares during the period. Millennium Management LLC increased its holdings in OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company's stock valued at $10,602,000 after buying an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of OPKO Health by 150.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company's stock worth $7,544,000 after acquiring an additional 3,600,378 shares during the period. UBS Group AG grew its position in shares of OPKO Health by 12.1% during the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company's stock valued at $6,745,000 after acquiring an additional 577,248 shares during the period. Finally, AWM Investment Company Inc. increased its stake in shares of OPKO Health by 8.1% in the 2nd quarter. AWM Investment Company Inc. now owns 2,000,000 shares of the biotechnology company's stock valued at $2,640,000 after purchasing an additional 150,000 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a report on Thursday, January 22nd. JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Thursday, November 20th. They issued a "neutral" rating for the company. Finally, Barrington Research reduced their target price on OPKO Health from $2.25 to $1.50 and set an "outperform" rating on the stock in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $2.03.

OPKO Health Company Profile

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.